Brought to you by 
Dompe licenses Provigil, Myotrophin from Cephalon
23 Sep 2014
Executive Summary
Italian pharmaceutical maker Dompe will market Provigil (modafinil) and Myotrophin (mecasermin) for Cephalon (CNS drugs) in Italy. Dompe will, upon approval, market the products to neurologists and other physicians through its sales force.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Dompe licenses Provigil, Myotrophin from Cephalon
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice